title: Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses.
abstract: BACKGROUND
  Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is not infrequent as both share same route of exposure. The risk of developing chronic hepatitis B virus is 6%, in general population but can reach 10-20% in HBV/HIV co-infected patients. When compared to general population, the response rate to HBV vaccine in HIV-infected patients is diminished, so previous studies have tried to improve this response using variety of schedules, doses and co-administration of immunomodulators. The purpose of this study was to evaluate two doses of recombinant HBV vaccine (10 or 40 microg), IM at 0, 1 and 6 months. Vaccination response was measured 30-50 days after last dose; titers of >9.9 IU/L were considered positive.
  
  
  RESULTS
  Seventy-nine patients were included, 48 patients (60.7%) serconverted. Thirty-nine patients (49.3%) received 10 microg vaccine dose, 24 patients (61.5%) seroconverted. Forty patients (50.7%) received 40 microg vaccine dose, 24 (60%) seroconverted. There were no differences between two doses. A statistically significant higher seroconversion rate was found for patients with CD4 cell counts at vaccination > or = 200 cel/mm3 (33 of 38 patients, 86.8%), compared with those with CD4 < 200 cel/mm3 (15 of 41, 36.6%), [OR 11.44, 95% IC 3.67-35.59, p = 0.003], there were no differences between two vaccine doses. Using the logistic regression model, CD4 count <200 cel/mm3 were significantly associated with non serologic response (p = 0.003). None other variables such as gender, age, risk exposure for HIV, viral load, type or duration of HAART or AIDS-defining illness, were associated with seroconversion.
  
  
  CONCLUSIONS
  In this study, an increase dose of HBV vaccine did not show to increase the rate of response in HIV infected subjects. The only significant findings associated to the response rate was that a CD4 count > or = 200 cel/mm3, we suggest this threshold at which HIV patients should be vaccinated.
authors.affiliation: Infectious Diseases, Instituto Nacional de Cancerología, Mexico City, México. Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14000 México, D.F, Mexico.
authors.forename: Patricia
authors.initials: P
authors.lastname: Cornejo-Juárez
authors.affiliation: Infectious Diseases, Instituto Nacional de Cancerología, Mexico City, México. Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14000 México, D.F, Mexico.
authors.forename: Patricia
authors.initials: P
authors.lastname: Volkow-Fernández
authors.affiliation: Infectious Diseases, Instituto Nacional de Ciencias Médicas y de la Nutrición. Salvador Zubirán, Mexico City, Mexico.
authors.forename: Kenia
authors.initials: K
authors.lastname: Escobedo-López
authors.affiliation: Infectious Diseases, Instituto Nacional de Cancerología, Mexico City, México. Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14000 México, D.F, Mexico.
authors.forename: Diana
authors.initials: D
authors.lastname: Vilar-Compte
authors.affiliation: Infectious Diseases, Instituto Nacional de Ciencias Médicas y de la Nutrición. Salvador Zubirán, Mexico City, Mexico.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Ruiz-Palacios
authors.affiliation: Infectious Diseases, Instituto Nacional de Ciencias Médicas y de la Nutrición. Salvador Zubirán, Mexico City, Mexico.
authors.forename: Luis Enrique
authors.initials: LE
authors.lastname: Soto-Ramírez